Foley) was 18.7 min in the mean, Aquablation time was 3.5 min, including 26 patients with >1 Aquablation passage due to prostate volume or configuration. Mean haemoglobin drop was 1.84 points, however, 8 patients (4.4%) needed transfusion of RBC. Secondary cautery due to delayed bleeding was necessary in 7 patients (3.9%). IPSS (21 (preop.) vs. 7 (3month) vs. 5.9 (6 month)); QoL (4.6 vs. 1.6 vs. 1.4); Qmax (11.4 ml/s (preop) vs. 20.1 ml/s (3 month)); PVR (187.8 ml (preop.) vs. 15 ml (3 month)) decreased significantly in the postoperative course. Antegrade ejaculation was preserved in 63% of the cases and 89% of the patients stated that based on their experience they would undergo the same surgery again.
INTRODUCTION AND OBJECTIVES:
Early reports of Aquablation (robotic, high-velocity waterjet prostate resection) for lower urinary tract symptoms due to benign prostatic hyperplasia suggest efficacy similar to that of TURP. We compare the safety and efficacy of prostate ablation using Aquablation (A) vs TURP (T).
METHODS: In this randomized, blinded, multi-center phase III trial, men with moderate-to-severe LUTS related to BPH were assigned to TURP or Aquablation. The primary safety endpoint was the occurrence of persistent CD Grade 1 or Grade 2 or higher operative complications at 3 months. The primary efficacy endpoint was the reduction in IPSS score at 6 months. Here we report 12 month data.
RESULTS: The mean baseline IPSS score, demographic profile, and mean prostate volume (T: 52 mL vs. A: 54 mL, p[0.31) were similar in both arms. Mean operative time was equivalent between the two groups (T: 35.5 vs. A:32.8 minutes, p[0.28), but mean resection time was significantly less in the Aquablation group (27 vs. 4 minutes, p<.0001).
The primary safety endpoint at 3 months occurred in 26% of Aquablation subjects and 42% of TURP subjects demonstrating superiority of Aquablation versus TURP. The overall rate of persistent anejaculation in sexually active men in the first 6 months occurred in 10% of Aquablation subjects and 38% of TURP subjects demonstrating superiority of Aquablation versus TURP.
Mean IPSS scores decreased from 22.9 at baseline to 5.9 at 6 months in the Aquablation group and from 22.2 at baseline to 6.8 in the TURP group demonstrating non-inferiority for the primary efficacy endpoint. The IPSS change scores for each arm at 12 months was 15.1 points (p[0.9940). The change in Qmax at 12 months was 10.3 for Aquablation and 10.6 for TURP (p[ns) .
Urodynamics studies were performed in 64 of the participating subjects at baseline and 6 month follow-up. At baseline Pdet/Qmax was 71.1 and 76.2 cm H20 in the Aquablation and TURP groups, respectively (p[0.5393). At 6-month follow-up, Pdet/Qmax decreased by 36 and 37 cm H20 respectively (p<0.0001) compared to baseline for both arms) with no significant difference in decrease across groups (p[0.8919).
CONCLUSIONS: Aquablation showed non-inferior symptom relief compared to TURP but with a lower risk of sexual dysfunction. The change in IPSS and Qmax at 12 months show similar durability for both Aquablation and TURP. Urologists employing minimally-invasive treatments (MIT) for BPH are faced with choosing among modalities that were studied in relation to sham surgery in separate pivotal studies but have not been compared in head to head fashion. The purpose of this analysis to simulate a direct comparison between WAVE and PUL with respect to efficacy by using the common sham procedure employed in the pivotal studies as a reference.
METHODS: PUL (UroLift System, Neotract) and convective WAVE (Rezum System, Boston Scientific) were compared by the Bucher method of indirect comparison using data extracted from published randomized double-blind sham-controlled trials (Rezum II Study, NCT01912339: LIFT Study, NCT01294150). The trials had similar designs, and the sham procedures were comparable between trials. The primary comparison was based on the treatment effect, defined as the treatment response in excess of the response to sham surgery, for each of International Prostate Symptom Score (IPSS) and peak urinary flow rate (Qmax) at three months. Durability of treatment response was assessed by freedom for retreatment (medical therapy or procedure to treat prostatic obstruction) through three years, on which treatments were compared using a life- Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
